Immunological Dynamics in Tumor Microenvironments

Over the last decade, the tumour microenvironment has emerged as a central determinant of cancer progression and response to therapy. Within this milieu, malignant cells, stromal compartments and infiltrating immune populations engage in bidirectional crosstalk that shapes local immunity. Cytotoxic lymphocytes such as CD8+ T cells encounter tumour antigens presented by both cancer cells and professional antigen-presenting cells. This recognition is modulated by co-stimulatory and co-inhibitory signals that govern T cell activation or exhaustion. Myeloid-derived suppressor cells and tumour-associated macrophages often create an immunosuppressive niche through soluble factors and cell-surface ligands, while stromal elements and the extracellular matrix act as physical barriers and direct regulators of immune cell trafficking. Metabolic competition for nutrients and the accumulation of reactive metabolites further skew effector functions. Understanding these multilayered interactions has underpinned advances in immunotherapy, from checkpoint inhibitors to engineered cell therapies, and revealed mechanisms of primary and acquired resistance. Recent investigations now integrate spatial, proteomic and single-cell approaches to map functional states across time and reveal novel targets to reprogram the tumour ecosystem towards durable anti-tumour immunity.

Research from Nature Portfolio

Recent studies have delineated a negative regulatory mechanism in CD8+ T cells that directly influences anti-tumour effector functions. Through genome-wide screening and proteomic analyses, a specific E3 ligase complex was identified as a checkpoint for T cell receptor and cytokine signalling. Genetic ablation of this ligase in preclinical models enhanced proliferation and cytotoxicity of tumour-specific T cells, while chemical inhibition of its activation restored interleukin signalling and boosted responses to CTLA-4 blockade. This work illuminates how post-translational modifications, such as neddylation, fine-tune T cell dynamics within tumours and offers a translational avenue for sensitising tumours to immunotherapy.

Research from all publishers

A novel cellular platform has been developed by decorating erythrocytes with peptide-MHC class I conjugates to directly activate antigen-specific CD8+ T cells. This approach triggered rapid expansion of tumour-antigen-recognising T cells in patient samples and achieved growth inhibition in mouse models, highlighting a cell-based vaccine strategy with potential for clinical translation. In parallel, temporal proteomic profiling across tumours and primary immune organs has mapped systemic immune phases during tumour progression, identifying early acute responses followed by adaptive activation and late-stage immune evasion. These datasets point to therapeutic windows for combined pathway inhibition to disrupt tumour-driven immunosuppression. Additionally, work in colorectal cancer models has revealed that activated T cells reprogram immunosuppressive myeloid populations by producing type I interferons and TNFα. This reprogramming induces apoptosis in suppressor cells and diminishes arginase-mediated T cell suppression, thereby potentiating the efficacy of PD-1 blockade and suggesting combinatorial regimens to overcome resistance.

Immunological Dynamics in Tumor Microenvironments publication trend

The graph below shows the total number of articles in immunological dynamics in tumor microenvironments across all publications each year (not limited to Nature Index journals).

Technical terms

Tumour microenvironment: The cellular and molecular milieu surrounding a tumour, including immune cells, stromal components and extracellular matrix.

CD8+ T cells: Cytotoxic lymphocytes that recognise antigenic peptides via the T cell receptor and can directly kill tumour cells.

Myeloid-derived suppressor cells (MDSCs): Immature myeloid cells that accumulate in tumours and suppress T cell and natural killer cell functions.

Immune checkpoint blockade: Therapeutic antibodies targeting co-inhibitory receptors (e.g. PD-1, CTLA-4) to reinvigorate exhausted T cells.

Neddylation: A post-translational modification attaching the ubiquitin-like protein NEDD8 to substrates, regulating protein stability and immune signalling.

Extracellular matrix: A network of proteins and polysaccharides in the tumour stroma that influences cell adhesion, migration and immune infiltration.

References

1. The CUL5 E3 ligase complex negatively regulates central signaling pathways in CD8+ T cells. Nature Communications (2024).
2. Developing an erythrocyte‒MHC-I conjugate for cancer treatment. Cell Discovery (2024).
3. Dynamic Proteomic Changes in Tumor and Immune Organs Reveal Systemic Immune Response to Tumor Development. Molecular & Cellular Proteomics (2024).
4. Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer. Signal Transduction and Targeted Therapy (2021).